CROI 2016 Program at a Glance

Keyword Index

KEYWORD INDEX

12-week use - 44LB , 153, 816, 932 2-LTR circles - 196, 211, 362, 745 2B4 - 161, 211 3TC - 281 4E10 epitope - 305, 976 4th-generation immunoassay - 521, 523, 964 –A– A20/TNFAIP3 - 235 Abacavir - 660, 661, 663 ABC-3TC - 297, 952 Abnormal uterine bleeding - 949 Acceptability - 156, 873, 883LB, 970, 1014 Access to care - 120, 122, 537, 587, 678, 902, 967, 968, 972, 1014, 1042, 1043 Acquired drug resistance - 229, 281, 305, 478, 495, 741LB Acquired immunodeficiency syndrome - 296, 302 Actigraphy - 305 Activation - 251, 290, 291, 302, 653, 826 Acute - 291 Acute Hepatitis C - 99, 154LB, 297, 536, 581, 590, 602 Acute HIV Infection - 13, 21, 87, 133, 188, 187, 219, 269, 287, 320, 349, 384, 404, 407, 414, 415, 418, 518, 521, 524, 727, 942, 927, 956, 964 Acute kidney injury - 763 Acute rejection - 572 Acute Retroviral Syndrome - 518 Acute SIV - 23, 274, 275LB Adaptor protein 2 (AP2) - 191 Adherence - 96, 99, 283, 476, 793, 795, 844, 873, 894, 919, 1029, 1034, 1039, 1055 Adherence to ART - 864, 940, 1019, 1022 Adipose tissue - 123, 271, 668, 702, 707 Adolescent and young people - 172, 174, 175, 176, 177, 442, 817, 822, 823, 829, 831, 833, 834, 835, 836, 845, 852, 854, 931, 936 Adults - 17, 55, 349, 419, 565, 640, 915, 940, 948 Adverse events - 667, 702, 855, 948 Abstracts - 478 ACA - 967, 1001

Africa - 28, 75LB, 109LB, 112, 113LB, 118, 120, 167, 212, 227, 419, 436, 564, 565, 624, 625, 676, 696, 771, 801LB, 833, 840, 843, 849, 901, 912, 937, 961, 977, 983, 985, 1019, 1021, 1022, 1042, 1063 African American - 52, 538LB, 883LB, 929 Age - 118, 220 Age specific estimates - 904 Aging - 145, 183, 279, 382, 396, 421, 646, 669, 670, 705, 709, 712, 715, 716, 719, 720, 721, 905, 938 AIDS - 265, 554, 614 AIDS Dementia Complex - 422 AIDS-related malignancy - 616 Albuminuria - 651 Alcohol - 150, 257, 277, 554, 568, 822, 911, 912 Amphotericin B deoxycholate - 763 Anal cancer - 620, 628, , 626, 633 Anal HPV subtyping - 626 Anal HSIL - 626 Anal intercourse – 887, 882LB Anal swabs - 628 Analytic treatment interruption (ATI) – 32LB, 92, 346, 347 Anatomical site - 331, 345 Anthropometric - 852 Anti-calcineurin immunosuppressive drugs - 162, 455 Anti-PD-L1 - 25 Antibodies - 15, 311LB, 504, 840 Antibody Neutralization - 15 Antibody response - 92, 318, 323, 830 Antibody-dependent cell-mediated cytotoxicity (ADCC) - 180, 181 Antigen/antibody assays - 521 Antiretroviral - 63, 71, 702, 961, 999, 1023 Antiretroviral agents - 32LB Antiretroviral drug - 16, 97, 395, 436, 461LB, 466, 505, 506, 662, 696 Antiretroviral drug transporters - 450 Antiretroviral failure - 833, 850, 940, 1031 Antiretroviral pharmacokinetics - 63, 433, 439, 440, 442, 443, 449, 453, 454, 774 Algorithm - 510, 521 Alpha 4 beta 7 - 287 ALVAC/AIDSVAX - 317

AntiretroviralTherapy (ART) - 16, 22, 41, 53, 87, 112, 118, 119, 121, 122, 126, 147, 151, 155, 160, 164, 167, 229, 252, 257, 265, 280, 290, 293, 330, 350, 384, 406, 418, 429, 434, 443, 445, 446, 462, 465, 473, 474, 475, 480, 491LB, 496, 512, 559, 561, 566, 567, 592, 613, 617, 618, 619, 621, 646, 660, 672, 677, 678, 679, 680, 692, 703, 707, 709, 728, 729, 734, 736, 751, 755, 761, 805, 812, 838, 844, 851, 853, 906, 910, 923, 930, 939, 940, 941, 944, 949, 954, 956, 957, 958, 989, 1003, 1020 • Adherence - 27, 834, 1031 • Care evaluation – 35LB, 1028 • Cascade - 119, 1014 • Coverage - 111, 163, 904, 954, 1023, 1025 • Initiation - 28, 38, 665, 1010, 1012, 1014 • Intensification - 950 • Naïve - 821 • Outcomes - 39, 122, 744, 771, 796, 813, 821, 845, 849, 943, 951, 1022, 1029, 1032 • Patients - 85, 860 • Programmonitoring - 119, 1013, 1041 • Scale-up - 122, 789, 860, 1012, 1023, 1041, 1056 • Switch – 953 • Atorvastatin adjunct therapy, Africa - 297 Antiretroviral tissue penetration - 447, 450, 874 Antiretroviral treatment - 55, 458, 552, 697, 788, 794, 800, 824, 840. 1017 Antituberculosis treatment - 155, 158LB 180, 458, 734, 741LB, 746, 753 Antiviral activity - 247, 464, 874

Antiviral Factor - 203 Antiviral therapy - 466 Anxiety - 414 APOBEC3 - 59, 199, 201, 629 APOBEC3F - 59 APOBEC3G/F - 81, 83, 629 APOBEC3H - 200 APOE - 145 Apoptosis - 243 Appointment reminders - 977 Archival HIV-1 - 140 Asia - 314, 349, 569, 831, 858 Aspergillosis - 764 Aspirin - 44LB Assay - 83 Association study - 937

Keyword Index

CROI 2016 165